Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)
Funding for research on Alzheimer's disease, with a focus on developing innovative products/services to prevent, treat, and care for patients.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: April 5, 2025 (Renewal/Resubmission/Revision) | September 5, 2025 (New & Renewal/Resubmission/Revision)
Funding Amounts: Phase I: up to $500,000 (2 years); Phase II: up to $2.5M (3 years) for AD/ADRD topics (with SBA waiver); typical ceiling $1,838,436 for Phase II
Summary: Supports small business-led research to develop innovative products, services, or technologies for the prevention, diagnosis, treatment, or care of Alzheimer's disease and related dementias.
Key Information: Updated March 2025: Align proposals with current NIH priorities; see full FOA for new requirements and foreign disclosure rules.
Description
This opportunity, offered by the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS) under the NIH Small Business Innovation Research (SBIR) program, funds research and development of innovative products, services, or technologies that advance the prevention, diagnosis, treatment, or care of Alzheimer's disease (AD) and AD-related dementias (ADRD). The program encourages commercialization of novel therapies, devices, diagnostics, and care solutions that can reduce the burden of AD/ADRD on individuals, families, and society.
Research areas of interest include, but are not limited to:
- Prevention: Interventions (behavioral, pharmacological, nutritional, etc.) to prevent or remediate neurodegenerative changes.
- Diagnosis: Development of sensitive, specific, and standardized diagnostic tools, biomarkers, imaging, biosensors, and machine learning tools for early detection and disease monitoring.
- Treatment: Discovery and evaluation of drugs, biologics, delivery systems, and clinical trials for cognitive and behavioral symptoms, including disease-modifying therapies.
- Care: Technologies and systems to support independent living, in-home care, telecare, assistive robotics, and culturally appropriate care delivery.
- Tools: Platforms for drug screening, data analytics, and tools to support caregivers and healthcare systems.
Both clinical trial and non-clinical trial applications are accepted.
